Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome.
Hoeks M, Bagguley T, van Marrewijk C, Smith A, Bowen D, Culligan D, Kolade S, Symeonidis A, Garelius H, Spanoudakis M, Langemeijer S, Roelofs R, Wiegerinck E, Tatic A, Killick S, Panagiotidis P, Stanca O, Hellström-Lindberg E, Cermak J, van der Klauw M, Wouters H, van Kraaij M, Blijlevens N, Swinkels DW, de Witte T; EUMDS Registry Participants. Hoeks M, et al. Among authors: culligan d. Leukemia. 2021 Jun;35(6):1745-1750. doi: 10.1038/s41375-020-01022-2. Epub 2020 Sep 18. Leukemia. 2021. PMID: 32948844 Free PMC article. No abstract available.
Erythropoietin and the myelodysplastic syndrome.
Jacobs A, Culligan D, Bowen D. Jacobs A, et al. Among authors: culligan d. Contrib Nephrol. 1991;88:266-70. doi: 10.1159/000419535. Contrib Nephrol. 1991. PMID: 2040188 No abstract available.
Lenalidomide monotherapy and in combination with cytarabine, daunorubicin and etoposide for high-risk myelodysplasia and acute myeloid leukaemia with chromosome 5 abnormalities.
Dennis M, Culligan D, Karamitros D, Vyas P, Johnson P, Russell NH, Cavenagh J, Szubert A, Hartley S, Brown J, Bowen D. Dennis M, et al. Among authors: culligan d. Leuk Res Rep. 2013 Aug 28;2(2):70-4. doi: 10.1016/j.lrr.2013.07.003. eCollection 2013. Leuk Res Rep. 2013. PMID: 24371786 Free PMC article.
Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry.
Mądry K, Lis K, Fenaux P, Bowen D, Symeonidis A, Mittelman M, Stauder R, Čermák J, Sanz G, Hellström-Lindberg E, Langemeijer S, Malcovati L, Germing U, Holm MS, Guerci-Bresler A, Culligan D, Sanhes L, Kotsianidis I, van Marrewijk C, Crouch S, de Witte T, Smith A; EUMDS Registry Participants. Mądry K, et al. Among authors: culligan d. Br J Haematol. 2023 Feb;200(4):451-461. doi: 10.1111/bjh.18542. Epub 2022 Nov 6. Br J Haematol. 2023. PMID: 36335984
Raising the standards of patient-centered outcomes research in myelodysplastic syndromes: Clinical utility and validation of the subscales of the QUALMS from the MDS-RIGHT project.
Efficace F, Koinig K, Cottone F, Bowen D, Mittelman M, Sommer K, Langemeijer S, Culligan D, Filanovsky K, Storck M, Smith A, van Marrewijk C, Dugas M, Stojkov I, Siebert U, de Witte T, Stauder R. Efficace F, et al. Among authors: culligan d. Cancer Med. 2023 Mar;12(6):7529-7539. doi: 10.1002/cam4.5487. Epub 2022 Dec 19. Cancer Med. 2023. PMID: 36533415 Free PMC article.
FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.
Othman J, Potter N, Mokretar K, Taussig D, Khan A, Krishnamurthy P, Latif AL, Cahalin P, Aries J, Amer M, Belsham E, Conneally E, Craddock C, Culligan D, Dennis M, Duncan C, Freeman SD, Furness C, Gilkes A, Gkreka P, Hodgson K, Ingram W, Jain M, King A, Knapper S, Kottaridis P, McMullin MF, Mohite U, Ngu L, O'Nions J, Patrick K, Rider T, Roberts W, Severinsen MT, Storrar N, Taylor T, Russell NH, Dillon R. Othman J, et al. Among authors: culligan d. Leukemia. 2023 Oct;37(10):2066-2072. doi: 10.1038/s41375-023-01994-x. Epub 2023 Aug 9. Leukemia. 2023. PMID: 37558736 Free PMC article.
100 results